Cutaneous T-cell lymphoma

Gilson D, Whittaker SJ, Child FJ, et al. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2019 Mar;180(3):496-526.Full text  Abstract

Willemze R, Hodak E, Zinzani P, et al; ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(4 suppl):iv30-40.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphoma [internet publication].Full text

1. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20;29(18):2598-607.Full text  Abstract

2. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019 Apr 18;133(16):1703-14.Full text  Abstract

3. Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009 May 21;113(21):5064-73.Full text  Abstract

4. Gilson D, Whittaker SJ, Child FJ, et al. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2019 Mar;180(3):496-526.Full text  Abstract

5. National Cancer Information Network. Registration of cutaneous T-cell lymphoma (CTCL) in England. Oct 2016 [internet publication].Full text

6. Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol. 2009 Feb;160(2):376-9. Abstract

7. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007 Jul;143(7):854-9.Full text  Abstract

8. Hinds GA, Heald P. Cutaneous T-cell lymphoma in skin of color. J Am Acad Dermatol. 2009 Mar;60(3):359-75; quiz 376-8. Abstract

9. Wu XC, Andrews P, Chen VW, et al. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol. 2009 Nov;33(5):337-46. Abstract

10. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA. 1988 Jul 1;260(1):42-6. Abstract

11. Crandon S, Yancey MA. Sezary syndrome: a case study of cutaneous T-cell lymphoma. Clin J Oncol Nurs. 2009 Apr;13(2):157-9. Abstract

12. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst. 1989 Oct 18;81(20):1560-7. Abstract

13. Zucker-Franklin D, Pancake BA. The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas. Semin Dermatol. 1994 Sep;13(3):160-5. Abstract

14. Sander CA, Simon M, Puchta U, et al. HHV-8 in lymphoproliferative lesions in skin. Lancet. 1996 Aug 17;348(9025):475-6. Abstract

15. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997 Jan 1;89(1):32-40.Full text  Abstract

16. Herne KL, Talpur R, Breuer-McHam J, et al. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003 Mar 15;101(6):2132-6.Full text  Abstract

17. Dalloul A, Laroche L, Bagot M, et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest. 1992 Sep;90(3):1054-60.Full text  Abstract

18. Thangavelu M, Finn WG, Yelavarthi KK, et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood. 1997 May 1;89(9):3371-7.Full text  Abstract

19. Wood GS, Schaffer JM, Boni R, et al. No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma. Am J Pathol. 1997 Feb;150(2):667-73.Full text  Abstract

20. Pawson R, Catovsky D, Schulz TF. Lack of evidence of HHV-8 in mature T-cell lymphoproliferative disorders. Lancet. 1996 Nov 23;348(9039):1450-1. Abstract

21. Myskowski PL. Cutaneous T-cell lymphoma and human immunodeficiency virus: the spectrum broadens. Arch Dermatol. 1991 Jul;127(7):1045-7. Abstract

22. Willemze R, Hodak E, Zinzani P, et al; ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(4 suppl):iv30-40.Full text  Abstract

23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphoma [internet publication].Full text

24. Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012 Aug;51(8):930-4. Abstract

25. Bi MY, Curry JL, Christiano AM, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011 Jan;64(1):53-63.Full text  Abstract

26. Kodama K, Fink-Puches R, Massone C, et al. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. J Am Acad Dermatol. 2005 Apr;52(4):694-8. Abstract

27. Boulos S, Vaid R, Aladily TN, et al. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol. 2014 Dec;71(6):1117-26. Abstract

28. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004 Jul;18(4):397-415. Abstract

29. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005 Dec;53(6):1053-63. Abstract

30. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15;110(6):1713-22.Full text  Abstract

31. Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obstet. 1944;79:352-8.

32. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998 Aug;134(8):949-54.Full text  Abstract

33. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005 Feb;52(2):275-80. Abstract

34. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol. 2006 Jul-Aug;16(4):391-3. Abstract

35. Martínez-González MC, Verea-Hernando MM, Yebra-Pimentel MT, et al. Imiquimod in mycosis fungoides. Eur J Dermatol. 2008 Mar-Apr;18(2):148-52. Abstract

36. Lewis DJ, Byekova YA, Emge DA, et al. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. J Dermatolog Treat. 2017 Sep;28(6):567-9. Abstract

37. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988 Oct;19(4):684-91. Abstract

38. Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003 Feb;139(2):165-73.Full text  Abstract

39. Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25-32.Full text  Abstract

40. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013 Jan;168(1):192-200. Abstract

41. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002 Mar;138(3):325-32.Full text  Abstract

42. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol. 1994 Sep;13(3):202-6. Abstract

43. Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16(4):299-302. Abstract

44. Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):109-15. Abstract

45. Ramsay DL, Lish KM, Yalowitz CB, et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol. 1992 Jul;128(7):931-3. Abstract

46. Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1995 Jan;13(1):257-63. Abstract

47. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71. Abstract

48. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001 May;137(5):581-93.Full text  Abstract

49. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986 Apr 15;57(8 suppl):1689-95.Full text  Abstract

50. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989 Mar;20(3):395-407. Abstract

51. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol. 1992 Dec;10(12):1907-13. Abstract

52. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol. 1994 Oct;12(10):2051-9. Abstract

53. Zackheim HS, Epstein EH Jr. Low-dose methotrexate for the Sezary syndrome. J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):757-62. Abstract

54. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep. 1979 Apr;63(4):691-700. Abstract

55. Reddy S, Parker CM, Shidnia H, et al. Total skin electron beam radiation therapy for mycosis fungoides. Am J Clin Oncol. 1992 Apr;15(2):119-24. Abstract

56. Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1027-35. Abstract

57. Maingon P, Truc G, Dalac S, et al. Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation. Radiother Oncol. 2000 Jan;54(1):73-8. Abstract

58. Fong S, Hong EK, Khodadoust MS, et al. Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and sézary syndrome. Adv Radiat Oncol. 2021 May-Jun;6(3):100629.Full text  Abstract

59. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015 Nov 10;33(32):3750-8.Full text  Abstract

60. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015 Nov 10;33(32):3759-65.Full text  Abstract

61. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-66. Abstract

62. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192-204. Abstract

63. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008 Sep 28;269(1):7-17. Abstract

64. Kim M, Thompson LA, Wenger SD, et al. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Ann Pharmacother. 2012 Oct;46(10):1340-8. Abstract

65. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109-15.Full text  Abstract

66. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31-9.Full text  Abstract

67. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol. 2008 Jun;144(6):727-33.Full text  Abstract

68. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012 Nov 20;30(33):4091-7.Full text  Abstract

69. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3;119(18):4115-22.Full text  Abstract

70. Foss F, Horwitz SM, Coiffier B, et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. Abstract

71. Talpur R, Thompson A, Gangar P, et al. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. Abstract

72. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000 Jul;18(13):2603-6. Abstract

73. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006 Jul;7(1):51-8. Abstract

74. Pellegrini C, Stefoni V, Casadei B, et al. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol. 2014 Nov;93(11):1853-7. Abstract

75. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003 Jun 1;101(11):4267-72.Full text  Abstract

76. de Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014 Mar;170(3):720-4. Abstract

77. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007 Jun;92(6):784-94.Full text  Abstract

78. Coors EA, von den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol. 2000 Jul;143(1):127-31. Abstract

79. Purnak S, Azar J, Mark LA. Etoposide as a single agent in the treatment of mycosis fungoides: a retrospective analysis. Dermatol Ther. 2018 Mar;31(2):e12586. Abstract

80. Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020 Jan 1;38(1):20-8.Full text  Abstract

81. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999 Oct;17(10):3117-21. Abstract

82. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol. 1991 Apr;9(4):565-71. Abstract

83. Greiner D, Olsen EA, Petroni G. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1997 Jun;36(6 Pt 1):950-5. Abstract

84. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Sep 20;25(27):4293-7.Full text  Abstract

85. de Masson A, Beylot-Barry M, Bouaziz JD, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014 Mar;99(3):527-34.Full text  Abstract

86. Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014 Nov;49(11):1360-5. Abstract

87. Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec;26(12):2490-5.Full text  Abstract

88. Domingo-Domenech E, Duarte RF, Boumedil A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021 Jun;56(6):1391-401. Abstract

89. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med. 1987 Feb 5;316(6):297-303. Abstract

90. Fraser-Andrews E, Seed P, Whittaker S, et al. Extracorporeal photopheresis in Sézary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol. 1998 Aug;134(8):1001-5.Full text  Abstract

91. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol. 1996 Dec;35(6):935-45. Abstract

92. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol. 1992 Sep;27(3):427-33. Abstract

93. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci. 2003 Feb;28(1):81-9. Abstract

94. Rook AH, Prystowsky MB, Cassin M, et al. Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations. Arch Dermatol. 1991 Oct;127(10):1535-40. Abstract

95. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol. 1996 Dec;35(6):946-57. Abstract

96. Cohen JH, Lessin SR, Vowels BR, et al. The sign of Leser-Trelat in association with Sezary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa. Arch Dermatol. 1993 Sep;129(9):1213-5. Abstract

97. Vonderheid EC, Bigler RD, Greenberg AS, et al. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol. 1994 Jun;17(3):255-63. Abstract

98. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct;9(5):1089-107. Abstract

99. Dippel E, Schrag H, Goerdt S, et al. Extracorporeal photopheresis and interferon-alfa in advanced cutaneous T-cell lymphoma. Lancet. 1997 Jul 5;350(9070):32-3. Abstract

100. Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999 Mar;140(3):427-31. Abstract

101. Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):987-95. Abstract

102. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):54-60. Abstract

103. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: T-cell lymphomas [internet publication].Full text

104. ClinicalTrials.gov. A trial of E7777 in persistent and recurrent cutaneous T-cell lymphoma. Jan 2022 [internet publication].Full text

105. ClinicalTrials.gov. Safety, PK, PD, clinical activity of KT-333 in adult patients with refractory lymphoma, large granular lymphocytic leukemia, solid tumors. Dec 2022 [internet publication].Full text

106. Yang Y, Wickless H. Thinking about CNS metastasis in cutaneous lymphoma: Analysis of existing data. Leuk Res Rep. 2017;8:14-18.Full text  Abstract

107. Bird TG, Whittaker S, Wain EM, et al. Temozolomide for central nervous system involvement in mycosis fungoides. Int J Dermatol. 2016 Jul;55(7):751-6. Abstract